Veracyte (VCYT) CFO executes Rule 10b5-1 stock sale

Rhea-AI Filing Summary

VERACYTE, INC. Chief Financial Officer Rebecca Chambers reported selling a total of 18,341 shares of common stock in open-market transactions on March 4, 2026. The sales were made under a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2025.

The transactions were executed at weighted average prices of $35.5476 and $36.3288 per share, with sale price ranges disclosed in the footnotes. Following these sales, the reporting person directly owned 131,196 shares of Veracyte common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chambers Rebecca

(Last) (First) (Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		S(1)		4,400	D	$35.5476(2)	145,137	D
Common Stock	03/04/2026		S(1)		13,941	D	$36.3288(3)	131,196	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.

2. Represents weighted average sales price. Sale prices for the transactions range from $35.00 to $35.99. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

3. Represents weighted average sales price. Sale prices for the transactions range from $36.01 to $36.55. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Remarks:

	/s/ Jonathan Wygant as attorney-in-fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Veracyte (VCYT) report for Rebecca Chambers?

Veracyte reported that Chief Financial Officer Rebecca Chambers sold 18,341 shares of common stock in open-market transactions on March 4, 2026. These sales were disclosed in a Form 4 filing and reflect routine insider trading activity reported to the SEC.

At what prices did the Veracyte (VCYT) CFO sell her shares?

The Veracyte CFO’s sales were executed at weighted average prices of $35.5476 and $36.3288 per share. Footnotes state the first group ranged from $35.00 to $35.99, and the second from $36.01 to $36.55, with detailed breakdowns available upon request.

How many Veracyte (VCYT) shares does the CFO hold after the sale?

After the reported transactions, Veracyte’s Chief Financial Officer directly owned 131,196 shares of common stock. This figure comes from the share balance shown after the second open-market sale reported in the Form 4 insider trading disclosure.

Was the Veracyte (VCYT) CFO’s stock sale under a Rule 10b5-1 plan?

Yes. A footnote explains the transactions were made under a Rule 10b5-1 trading plan adopted by the reporting person on August 21, 2025. Such plans pre-schedule trades, helping insiders diversify holdings while following securities regulations.

How many total Veracyte (VCYT) shares did the CFO sell in this Form 4?

The Form 4 shows that the Veracyte CFO sold a total of 18,341 shares of common stock across two open-market sales. Each transaction lists the number of shares sold, and a summary indicates the combined net activity was a net-sell of 18,341 shares.

What does a Form 4 insider sale mean for Veracyte (VCYT) investors?

A Form 4 insider sale records that a company insider traded the stock and must be disclosed to the SEC. In this case, the CFO’s planned sales under a Rule 10b5-1 plan represent personal portfolio activity rather than a stated change in company fundamentals.